Rapid Therapeutic Science Laboratories (RTSL) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 14, 2023
Details
Registrant CIK	0001575659
Fiscal Year End	--12-31
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	000-55018
Entity Registrant Name	Rapid Therapeutic Science Laboratories, Inc.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	46-2111820
Entity Address, Address Line One	558 County Road 472
Entity Address, City or Town	De Leon
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	76444
City Area Code	800
Local Phone Number	497-6059
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,832,251
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 2,160	$ 0
Employer tax refund receivable	82,529	0
Inventory, net	175,047	175,047
Prepaid expenses	58,146	58,146
Total current assets	317,882	233,193
Property and equipment:
Property and equipment, gross	1,354,072	1,564,503
Accumulated depreciation	(65,313)	(53,327)
Net property and equipment	1,288,759	1,511,176
Other long-term assets
Operating lease right-of-use asset, net	297,619	340,136
Sublicense agreement, net	170,075	170,075
Total assets	2,074,335	2,254,580
Current liabilities
Accounts payableand accrued liabilities, net	769,957	891,408
Promissory notes payable - related party	841,560	820,602
Convertible notes payable - other	2,455,791	2,481,333
Accrued interest payable	173,856	124,736
Current portion of operating lease obligation	100,650	98,509
Warrant liability	30,195	508,593
Derivative liability	53,568	40,647
Total current liabilities	4,425,577	4,965,828
Long-term liabilities
Convertible notes payable	150,000	150,000
Long-term portion of operating lease obligation	237,892	280,235
Total liabilities	4,813,469	5,396,063
Stockholders' deficit
Preferred stock value	0	0
Common stock value	8,832	7,763
Additional paid in capital	7,667,829	7,504,242
Accumulated deficit	(10,078,456)	(10,316,149)
Treasury stock	(337,339)	(337,339)
Total stockholders' deficit	(2,739,134)	(3,141,483)
Total liabilities and stockholders' deficit	$ 2,074,335	$ 2,254,580

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets - Parenthetical - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred Stock, Par or Stated Value Per Share	$ 0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	800,000,000	800,000,000
Common Stock, Shares, Outstanding	8,832,251	7,764,594
Series A Preferred Stock
Preferred Stock, Shares Authorized	16,500,000
Series B Preferred Stock
Preferred Stock, Shares Authorized	2,000,000
Series C Preferred Stock
Preferred Stock, Shares Authorized	8,500,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Condensed Consolidated Statements of Operations
Revenues	$ 0	$ 0	$ 0	$ 0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
Operating expenses
General and administrative expense	97,739	122,382	190,040	905,782
Depreciation expense	5,993	5,993	11,986	11,986
Total operating expenses	103,732	128,375	202,026	917,768
Other income (expense)
Gain (loss) on valuation of warrant liability	128,456	857,127	529,047	780,082
Interest expense	(60,831)	(765,590)	(171,857)	(1,478,903)
Refund of prior year employer taxes	82,529	0	82,529	0
Total other income (expense)	150,154	91,537	439,719	(698,821)
Net income (loss) before income taxes	46,422	(36,838)	237,693	(1,616,589)
Income taxes	0	0	0	0
Net income (loss)	$ 46,422	$ (36,838)	$ 237,693	$ (1,616,589)
Net income (loss) per share, basic and diluted	$ 0.01	$ 0	$ 0.03	$ (0.21)
Weighted average shares outstanding, basic and diluted	8,318,055	7,746,687	8,149,758	7,745,759

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations - Parenthetical - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Condensed Consolidated Statements of Operations
Amortization expense	$ 21,259	$ 42,517

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock, Common	Total
Equity Balance at Dec. 31, 2021	$ 7,743	$ 7,469,262	$ (8,521,423)	$ (337,339)	$ (1,381,757)
Equity Balance, Shares at Dec. 31, 2021	7,742,687
Net income (loss)	$ 0	0	(1,579,751)	0	(1,579,751)
Equity Balance at Mar. 31, 2022	$ 7,747	7,489,258	(10,101,174)	(337,339)	(2,941,508)
Equity Balance, Shares at Mar. 31, 2022	7,746,687
Share-based compensation, value	$ 4	19,996	0	0	20,000
Share-based compensation, shares issued	4,000
Equity Balance at Dec. 31, 2021	$ 7,743	7,469,262	(8,521,423)	(337,339)	(1,381,757)
Equity Balance, Shares at Dec. 31, 2021	7,742,687
Net income (loss)					(1,616,589)
Equity Balance at Jun. 30, 2022	$ 7,747	7,548,468	(10,138,012)	(337,339)	(2,919,136)
Equity Balance, Shares at Jun. 30, 2022	7,746,687
Equity Balance at Dec. 31, 2021	$ 7,743	7,469,262	(8,521,423)	(337,339)	(1,381,757)
Equity Balance, Shares at Dec. 31, 2021	7,742,687
Equity Balance at Dec. 31, 2022	$ 7,763	7,504,242	(10,316,149)	(337,339)	(3,141,483)
Equity Balance, Shares at Dec. 31, 2022	7,764,594
Equity Balance at Mar. 31, 2022	$ 7,747	7,489,258	(10,101,174)	(337,339)	(2,941,508)
Equity Balance, Shares at Mar. 31, 2022	7,746,687
Net income (loss)	$ 0	0	(36,838)	0	(36,838)
Equity Balance at Jun. 30, 2022	$ 7,747	7,548,468	(10,138,012)	(337,339)	(2,919,136)
Equity Balance, Shares at Jun. 30, 2022	7,746,687
Share-based compensation, value	$ 0	59,210	0	0	59,210
Share-based compensation, shares issued	0
Equity Balance at Dec. 31, 2022	$ 7,763	7,504,242	(10,316,149)	(337,339)	(3,141,483)
Equity Balance, Shares at Dec. 31, 2022	7,764,594
Stock issued for conversion of debt, value	$ 319	112,337	0	0	112,656
Stock issued for conversion of debt, shares	317,803
Net income (loss)	$ 0	0	191,271	0	191,271
Equity Balance at Mar. 31, 2023	$ 8,082	7,616,579	(10,124,878)	(337,339)	(2,837,556)
Equity Balance, Shares at Mar. 31, 2023	8,082,397
Equity Balance at Dec. 31, 2022	$ 7,763	7,504,242	(10,316,149)	(337,339)	(3,141,483)
Equity Balance, Shares at Dec. 31, 2022	7,764,594
Net income (loss)					237,693
Equity Balance at Jun. 30, 2023	$ 8,832	7,667,829	(10,078,456)	(337,339)	(2,739,134)
Equity Balance, Shares at Jun. 30, 2023	8,832,251
Equity Balance at Mar. 31, 2023	$ 8,082	7,616,579	(10,124,878)	(337,339)	(2,837,556)
Equity Balance, Shares at Mar. 31, 2023	8,082,397
Stock issued for conversion of debt, value	$ 350	11,650	0	0	12,000
Stock issued for conversion of debt, shares	349,854
Net income (loss)	$ 0	0	46,422	0	46,422
Equity Balance at Jun. 30, 2023	$ 8,832	7,667,829	(10,078,456)	(337,339)	(2,739,134)
Equity Balance, Shares at Jun. 30, 2023	8,832,251
Stock issued for cash, value	$ 400	$ 39,600	$ 0	$ 0	$ 40,000
Stock issued for cash, shares	400,000				400,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net income (loss)	$ 237,693	$ (1,616,589)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operations
Gain (loss) on valuation of warrant liability	(529,047)	(780,082)
Amortization of debt discount	83,355	1,342,180
Non-cash interest	30,329	0
Stock-based compensation expense	0	79,210
Depreciation expense	11,986	11,986
Amortization of Right of use asset	42,517	42,517
Other non-cash expenses	58,659	0
Changes in operating assets and liabilities
Increase (decrease) in other current assets	(82,529)	6,608
Increase (decrease) in accounts payable and accrued liabilities	48,778	244,658
Increase (decrease) in Accrued interest payable	49,120	35,265
Increase (decrease) in other current liabilities	0	0
Net cash flows used in operating activities	(49,139)	(634,247)
Cash flows from investing activities
Additions to property and equipment	0	(354,800)
Net cash flows used in investing activities	0	(354,800)
Cash flows from financing activities
Proceeds from issuance of common stock	40,000	0
Proceeds from notes payable - related party	0	423,000
Proceeds from notes payable - other	50,000	525,127
Payment of notes payable	(38,701)	0
Payment of notes payable - other	0	(39,400)
Net cash flows provided by financing activities	51,299	908,727
Net increase (decrease) in cash and cash equivalents	2,160	(80,320)
Cash and cash equivalents at beginning of period	0	192,484
Cash and cash equivalents at end of period	2,160	112,164
Supplemental cash flow data
Cash paid for interest	0	3,352
Cash paid for income taxes	0	0
Supplemental non-cash financing activities
Convertible notes and accrued interest converted to common stock	124,656	0
Accounts payable for additions to property and equipment	$ (210,431)	$ 307,879

Condensed Interim Financial Sta

Condensed Interim Financial Statements	6 Months Ended
	Jun. 30, 2023
Notes
Condensed Interim Financial Statements	(1) Condensed Interim Financial Statements The Company we our Company Interim Financial Information SEC Impact of COVID-19 Pandemic on Consolidated Financial Statements COVID-19

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Notes
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies Basis of Accounting Reverse Stock Split Principles of Consolidation Cash and Cash Equivalents Inventory Property and Equipment Intangible Assets Revenue recognition FASB ASU Revenue from Contracts with Customers (Topic 606) Earnings per Share Income Taxes Use of Estimates Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from estimates. Fair Value of Financial Instruments Level 1: The preferred inputs to valuation efforts are “ quoted prices in active markets for identical assets or liabilities Level 2: FASB acknowledged that active markets for identical assets and liabilities are relatively uncommon and, even when they do exist, they may be too thin to provide reliable information. To deal with this shortage of direct data, the board provided a second level of inputs that can be applied in three situations. Level 3: If inputs from levels 1 and 2 are not available, FASB acknowledges that fair value measures of many assets and liabilities are less precise. The board describes Level 3 inputs as “ unobservable shall be used to measure fair value to the extent that observable inputs are not available for situations in which there is little, if any, market activity for the asset or liability at the measurement date observable inputs The Company’s financial instruments consist of cash, tax refund receivable, accounts payable and accrued liabilities, notes payable, due to related parties, warrant liabilities and derivative liabilities. Except for cash, warrant liabilities, and derivative liabilities, the Company’s financial instruments’ carrying amounts, excluding unamortized discounts, approximate their fair values due to their short term to maturity. Cash is measured and recognized at fair value based on level 1 inputs for all periods presented. Warrant liabilities and Derivative liabilities are measured and recognized at fair value based on level 3 inputs. Recently Issued Accounting Pronouncements Subsequent Events

Going Concern Disclosure

Going Concern Disclosure	6 Months Ended
	Jun. 30, 2023
Notes
Going Concern Disclosure	(3) Going Concern The Company's consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has generated minimal revenues and has suffered recurring losses totaling $10,078,456 since inception and has a working capital deficit as of June 30, 2023 of $4,107,695. These factors, among others, indicate that there is substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of this filing. In order to obtain the necessary capital to sustain operations, management’s plans include, among other things, the possibility of pursuing new equity sales and/or making additional debt borrowings. There can be no assurances, however, that the Company will be successful in obtaining such additional financing, or that such financing will be available on favorable terms, if at all. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from the outcome of this uncertainty.

License Agreement Disclosure

License Agreement Disclosure	6 Months Ended
	Jun. 30, 2023
Notes
License Agreement Disclosure	(4) License Agreement The Company has acquired certain intangible asset rights to use the metered dose inhaler (MDI) developed by EM3 Methodologies, LLC (“ EM3 EM3 Exclusive License Effective November 15, 2019, we entered into a sublicense agreement (the “ TMDI Agreement TMDI Original EM3 Exclusive License cannabis, hemp or a combination thereof in any legal jurisdiction, in consideration for the issuance of 5,600,000 shares of the Company’s common stock. Such rights were recorded as the acquisition of an intangible asset in the amount of $140,000, based on the then fair value of the shares issued. Effective February 9, 2021, both the TMDI Agreement and the Original EM3 Exclusive License were effectively terminated by mutual agreement of all parties with no additional consideration beyond the original shares issued and EM3 agreed to provide the Company with a royalty-free, perpetual license to use the Desirick Procedure or any derivation thereof and its application and use on an exclusive basis in the states of Texas, California, Florida and Nevada (subject to pre-existing licensing rights which have been provided by EM3 in such jurisdictions), and on a non-exclusive basis throughout the rest of the world. During the term of the TMDI Agreement, we were required to reimburse TMDI for the initial two year license fee owed by TMDI to EM3 in the amount of $200,000. We partially satisfied this obligation by making an equipment purchase on behalf of EM3 in the amount of $135,000, and agreed to pay the remaining license fee of $65,000, either by making cash fee payments or by making cash purchases of certain supplies from EM3, within a 24-month period (for which, we had recorded a liability of $44,925 for the unpaid portion of this amount in accounts payable as of December 31, 2020). We had recorded the entire $200,000 license fee as an intangible asset and were amortizing such expense on a straight-line basis over a 24-month period at the rate of $25,000 per quarter. Pursuant to the termination of the two agreements on February 9, 2021, we no longer owe TMDI (or EM3) any license fees under either agreement (including, the accrued liability of $44,925). Effective as of February 2021, the Company is accounting for the licenses as an indefinite life asset not subject to amortization, resulting in the remaining balance of $170,075 being subjected to impairment testing at least annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.

Prior Asset Acquisition Disclos

Prior Asset Acquisition Disclosure	6 Months Ended
	Jun. 30, 2023
Notes
Prior Asset Acquisition Disclosure	(5) Prior Asset Acquisition On November 16, 2020, the Company closed an Asset Purchase and Sales Agreement with Razor Jacket, LLC (“ Razor Jacket RJ Agreement The Company has accounted for this transaction as an acquisition of assets at fair value, pursuant to the provisions of Accounting Standards Codification (ASC) 805-50. Accordingly, we have accounted for each component of the purchase price as follows: · · · Razor Jacket was originally formed in July 2019 for the sole purpose of researching techniques for the extraction of isolates from raw hemp. We have not presented any pro forma disclosures relating to this acquisition in the notes to our financial statements because the transaction is deemed an asset acquisition.

Property and Equipment Disclosu

Property and Equipment Disclosure	6 Months Ended
	Jun. 30, 2023
Notes
Property and Equipment Disclosure	(6) Property and Equipment As of June 30, 2023, and December 31, 2022, the Company had the following balances of property and equipment: June 30, 2023 December 31, 2022 Equipment purchased from Razor Jacket, LLC and awaiting installation in the Company’s facilities in Addison, Texas $ 500,000 $ 500,000 Equipment located in the Company’s facilities in Dallas, Texas 221,412 221,412 Leasehold improvements in progress at the Company’s new facilities in Addison, Texas 630,160 840,591 Leasehold improvements in the Company’s existing facilities in Dallas, Texas 2,500 2,500 Total property and equipment 1,354,072 1,564,503 Less: Accumulated depreciation (65,313) (53,327) Net property and equipment $ 1,288,759 $ 1,511,176 Effective October 1, 2021, the Company entered into a lease agreement with a landlord to lease 8,566 square feet of commercial office building space located in Addison, Texas (see Note 8). As of December 31, 2022, the Company was in the process of building out this space, while obtaining any necessary governmental approvals, with the intention of utilizing it as its corporate office as well as its aerosol filling laboratory and isolate manufacturing facility, however, the Company recently suspended such activities pending a determination of the feasibility of continuing the project. As of June 30, 2023, the Company had capitalized leasehold improvements in progress at the new location in the amount of $630,160, of which $100,000 had not been paid and is reflected in Accounts Payable as of that date. Based on the current facts and circumstances of this matter as well as management’s assessment of the situation in accordance with current accounting standards, the Company believes that the recent suspension of the project is largely temporary at this point and has not caused an impairment in the value of such capital costs. Since part of the Company’s decision to delay the project is based on permitting issues, the timing of which can often be unpredictable, it is difficult to project when such delay will terminate. In the meantime, however, we will continue to monitor the situation for any indication of potential impairment. The equipment purchased from Razor Jacket, LLC in November 2020 has been shipped to a secure location in Texas, where it is awaiting installation in the new location, referenced above, or in a possible alternate location (see Note 5).

Notes Payable Disclosure

Notes Payable Disclosure	6 Months Ended
	Jun. 30, 2023
Notes
Notes Payable Disclosure	(7) Notes Payable As of June 30, 2023 and December 31, 2022, the Company had the following note payable obligations: June 30, 2023 December 31 2022 Non-Related Parties Convertible debenture issued to an accredited investor on August 4, 2021, in principal amount of $1,941,176, original issue discount of 15%, convertible at option of investor into a total of 194,118 shares of common stock at $10.00 per share, payable upon earlier of a qualified offering, uplisting on national exchange, convertible at 25% discount to the price per share of common stock in a qualified offering, past due nominal maturity. $ 1,941,176 $ 1,941,176 Convertible debenture issued to an accredited investor on May 31, 2022, in principal amount of $411,764, original issue discount of 15%, convertible at option of investor into a total of 41,176 shares of common stock at $10.00 per share, payable upon earlier of a qualified offering, uplisting on national exchange, convertible at 25% discount to the price per share of common stock in a qualified offering, past due nominal maturity. 411,764 411,764 Convertible promissory notes issued to an accredited investor on November 15, 2019, maturing in 5 years, accruing interest at 5% per annum, convertible into common stock at $1.25 per share. 150,000 150,000 Other short term notes issued to various affiliates of the former owners of Power Blockchain for acquisition of Treasury Stock, computers and equipment, and working capital financing, at stated interest rates of 10%. Amended on November 15, 2019, to be convertible into common stock at $1.25 per share. Of this amount, $23,700 pertains to a related party. 48,386 48,386 Promissory note issued to an institutional investor on March 8, 2022, accruing interest at approximately 8% per annum, due in one year, in default and fully converted as of June 30, 2023. - 70,104 Convertible note issued to an accredited investor on July 25, 2022, net of unamortized debt discount of $4,933 and partial conversion of $12,000 (see further discussion below). 57,317 33,603 Convertible note issued to an accredited investor on February 3, 2023, net of unamortized debt discount of $32,401 (see further discussion below). 21,849 - Related Parties Unsecured advances received from two officers beginning in May 2021 and continuing through March 2023, accruing interest at 1% per annum, payable on demand. 416,860 396,902 Promissory note issued to an independent director on January 28, 2022, accruing interest at approximately 18% per annum, currently past due nominal maturity. 400,000 400,000 Total notes payable 3,447,352 3,451,935 Current portion of notes payable (3,297,352) (3,301,935) Long term portion of notes payable $ 150,000 $ 150,000 Future maturities of notes payable as of June 30, 2023, without taking into account the unamortized debt discount, are as follows: Year ending June 30, 2024 $ 3,334,686 Year ending June 30, 2025 150,000 $ 3,484,686 On August 4, 2021, the Company closed what was originally contemplated to be a short-term bridge loan with an institutional investor in the gross amount of $1,941,176. The closing of this bridge loan resulted in net proceeds to the Company of $1,650,000, after deducting the 15% original issue discount. The Company accreted such discount as a non-cash charge to interest expense over the original term of the loan, which was extended in May 2022, as further discussed below. Additionally, we granted the investor warrants to purchase a total of 194,118 shares of our common stock at an exercise price of $10.00 per share for a period of five years, which was extended by two years in May 2022, as further discussed below. The bridge loan is in the form of a debenture which is convertible into shares of the Company’s common stock at the lower of: (a) (b) The bridge loan was originally structured with a maturity date in May 2022, however, due to unforeseen delays experienced in the Company’s planned public offering of common stock on a national exchange, we were unable to repay or convert it by that date. On May 31, 2022, we reached a formal agreement with the institutional investor to extend the maturity of our existing Convertible Debenture in the amount of $1,941,176, until the earlier of (i) the completion of a qualified offering, (ii) an uplisting on a national exchange, or (iii) September 1, 2022, and simultaneously issued a new Convertible Debenture to the institutional investor payable for additional borrowings in the gross amount of $411,764, on substantially equivalent terms. The note is past due its nominal maturity date, however, the lender has not declared it to be in default. As a result of the formal extension agreement reached with the institutional investor in May 2022, we restructured our specific obligations to this investor as follows: · · · · Following the issuance of the initial Convertible Debenture in August 2021, the Company early adopted the provisions of ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. We elected to apply this new accounting principle to the subject convertible borrowings using the modified retrospective method. Pursuant to the provisions of ASC 470-60-35-5 with regard to debt modifications, we have accounted for the extension of the maturity of the initial Convertible Debenture in May 2022, on a prospective basis and, therefore, did not adjust any previously recorded amounts. The two tranches of Common Stock Purchase Warrants that we have granted to the investor in August 2021 and May 2022, as well as a grant of warrants that we made in August 2021 to the placement agent for the bridge loan to purchase a total of 9,706 shares of our common stock at an exercise price of $10.00 per share, with substantially similar terms, are subject to certain ownership limitations and adjustment provisions. These warrants also require the Company, at the holder’s option, following a Fundamental Transaction (as defined in the agreement), to purchase the warrants from the holder in cash, based on the Black Scholes value (as calculated pursuant to the terms of the warrant). As a result of this provision, the Company accounted for the issuance of the initial tranche of 203,824 warrants in August 2021 (including 9,706 shares to the placement agent) as a liability recorded at fair value in accordance with ASC 480-10. Using the Black Scholes model, the warrant liability was valued at issuance in the amount of $1,717,213 and has been subsequently adjusted to its current fair value as of each quarterly reporting date. As of June 30, 2023, we adjusted the warrant liability to its current fair value of $10,395, based on the Black Scholes model, resulting in a gain on warrant liability of $130,220 that was recorded in our statement of operations for the six months ended June 30, 2023. The Company has also accounted for the issuance of the additional tranche of 388,236 warrants in May 2022 as a liability recorded at fair value in accordance with ASC 480-10. Using the Black Scholes model, such warrant liability was valued at issuance in the amount of $756,285. This liability was recorded as a discount to the convertible debt of $350,000 with the excess $406,285 expensed as interest. The Company is accreting the debt discount, along with the original issue discount on the convertible debt, to interest expense over the term of the convertible debenture and such debt discount was fully accreted as of September 1, 2022. As of June 30, 2023, we adjusted the warrant liability to its current fair value of $19,800, based on the Black Scholes model, resulting in a gain on warrant liability of $348,178 that was recorded in our statement of operations for the six months ended June 30, 2023. Prior to obtaining the bridge loan noted above, the Company received a series of unsecured cash advances from two of its officers beginning in May 2021 through June 2023, in the net amount of $416,860. These related party advances accrue interest at the rate of 1% per annum and are payable on demand. Such advances were originally expected to be repaid out of the proceeds of a planned public or private offering of the Company’s equity, however, no assurance can be given that the Company will be successful in achieving a closing of such an offering. On February 3, 2023, the Company closed a short-term loan with an institutional investor in the gross amount $54,250. The closing of this loan resulted in net proceeds to the Company of approximately $50,000, after deducting the original issue discount and transaction fees. The note has a maturity date of one year after the date of issuance and bears interest at a rate of 9% per annum, which is not due until maturity. At the option of the investor, the note may be converted into shares of the Company’s common stock at a conversion price equal to the greater of (a) $0.000075 per share; and (b) 65% of the average closing bid price of the Company’s common stock, on the principal securities exchange or market where the Company’s common stock is then quoted or traded, for the three (3) lowest trading prices during the fifteen (15) Trading Day period ending on the latest complete trading day prior to the conversion date. The Company determined that the conversion feature of the note required the recognition of a derivative liability upon issuance and calculated the fair value of the derivative liability, using the Black Scholes model, to be $63,570. Accordingly, the Company has recognized a derivative liability in that amount offset by a debt discount which it is amortizing over the one year term of the note. As of June 30, 2023, we adjusted the derivative liability to its current fair value, resulting in a gain on derivative liability of $9,496 that was recorded in our statement of operations for the six months ended June 30, 2023. On July 25, 2022, the Company entered into an agreement with the same accredited investor (the “Buyer”) with respect to a Convertible Promissory Note (the “Note”) issued by the Company to the Buyer in the amount of $74,250. The Note has a maturity date of one year after the date of issuance and bears interest at a rate of 9% per annum, which is not due until maturity. At the option of the Buyer, the Note may be converted into shares of the Company’s common stock, beginning 180 days following the date of issuance. Under this option, the conversion price shall be subject to a discount of 35%, based on the average of the three (3) lowest closing bid prices for the Common Stock during the prior fifteen (15) trading day period. The Buyer will be limited to convert no more than 4.99% of the issued and outstanding Common Stock at time of conversion at any one time. The Company determined that the conversion feature of the Note required the recognition of a derivative liability upon issuance. As of July 25, 2022, the Company calculated the fair value of the derivative liability, using the Black Scholes model, to be $72,020. Accordingly, the Company has recognized a derivative liability in that amount offset by a debt discount. The Company is amortizing the debt discount over the one year term of the Note. As of May 26, 2023, the Buyer elected to convert $12,000 of the note principal into 349,854 shares of our common stock at the calculated conversion rate. As of June 30, 2023, we adjusted the derivative liability to its current fair value, resulting in a gain on derivative liability of $40,955 that was recorded in our statement of operations for the six months ended June 30, 2023. In January and March 2022, the Company closed two short-term loans from two different lenders in the total amount of $597,000. One of these loans was from an independent director of the Company in the amount of $400,000. Both loans were in the form of unsecured promissory notes bearing interest at rates of approximately 8-18% per annum with a maturity of one year. For the larger note with an independent director, the principal amount and accrued interest are due at the maturity date, which the director has agreed to extend to a date to be determined, whereas for the smaller note with an institutional investor, monthly payments of principal and interest of $21,276 were required beginning in May 2022. In the event of a default by the Company on the payment terms of either note, the notes would be convertible into shares of the Company’s common stock at a conversion price equal to the greater of (a) $0.001875 per share; and (b) 75% of the average closing bid price of the Company’s common stock, on the principal securities exchange or market where the Company’s common stock is then quoted or traded, for the five trading days immediately prior to the date of conversion. In December 2022, we defaulted on making the monthly note payment of $21,276 to the institutional investor due to our lack of liquidity which resulted in the investor electing to convert $15,000 of the note principal into 16,340 shares of our common stock, at the calculated conversion rate, leaving a then remaining outstanding loan balance, including default interest, of $70,104. In January and February 2023, the investor elected to fully convert the $70,104 balance of the note, plus an additional default penalty of $42,552, into a total of 317,803 shares of our common stock, at the applicable conversion rates at the time of each conversion (see Note 9). Effective March 31, 2021 and August 31, 2020, the Company reached the necessary milestones to trigger the conversion of certain notes payable issued on various dates in 2018 and 2019, as amended, into shares of the Company’s common stock, at conversion prices of $1.25 to $3.25 per share, subject to a 4.99% ownership limitation for each beneficial owner of such notes. In conjunction with these conversions, the holders of notes with total principal and accrued interest balances in the aggregate amount of $794,358 converted their notes into 433,203 shares of common stock, effective March 31, 2021, and the holders of notes with total principal and accrued interest balances in the aggregate amount of $501,137 converted their notes into 400,910 shares of common stock, effective August 31, 2020. As of June 30, 2023, convertible notes payable in the amount of $174,685, plus accrued interest in the amount of $53,568, remain outstanding and are available to be subsequently converted into 182,602 shares of common stock, subject to the ownership limitation (see Note 9). Effective November 15, 2019, the following transactions took place in the Company’s notes payable: · · · With respect to the transactions noted above, the Company performed an analysis of the newly issued convertible notes and the newly amended existing notes, which were formerly non-convertible in accordance with then applicable accounting standards. As a result, we determined that no adjustment to the amended notes were required.

Long Term Lease Obligation Disc

Long Term Lease Obligation Disclosure	6 Months Ended
	Jun. 30, 2023
Notes
Long Term Lease Obligation Disclosure	(8) Long Term Lease Obligation Effective October 1, 2021, the Company entered into a lease agreement with a landlord to lease 8,566 square feet of commercial office building space located in Addison, Texas (see Note 6). The lease agreement is for a total term of 63 months, beginning October 1, 2021 and ending December 31, 2026. As of December 31, 2022, the Company was in the process of building out this space, while obtaining any necessary governmental approvals, with the intention of utilizing it as its corporate office as well as its aerosol filling laboratory and isolate manufacturing facility, however, the Company recently suspended such activities pending a determination of the feasibility of continuing the project. We are accounting for the lease agreement as an operating lease under ASU 2016-02, Leases (Topic 842). Accordingly, the Company has capitalized the present value of the future lease obligations and is amortizing the related right-of-use asset on a straight-line basis each month over the term of the lease. Due to our recent liquidity situation, we have been in arrears in the payment of the monthly rent, however, the landlord has not declared us to be in default of the lease agreement and currently we are in discussion with landlord to renegotiate lease terms. Therefore, we have reflected such unpaid amounts in accounts payable as of June 30, 2023. As a result of our recent decision to temporarily suspend the build out of this leased space, as noted above, management has also performed an assessment of the net book cost of the right-of-use asset, similar to the assessment that was performed with respect to the capitalized costs of the improvements that have been made in the leased space, in accordance with current accounting standards, and believes that the recent temporary suspension of the project has not caused an impairment in the value of such asset (see Note 6). Total operating lease minimum payments, together with their present values as of June 30, 2023, are summarized as follows: Year ending December 31, 2023 $ 44,972 Year ending December 31, 2024 102,792 Year ending December 31, 2025 107,075 Year ending December 31, 2026 111,358 Total future minimum lease payments 366,197 Less amounts representing interest (27,655) Present value of lease liability 338,542 Current portion of operating lease liability (100,650) Long-term portion of operating lease liability $ 237,892 As of June 30, 2023, the operating lease right-of-use asset and operating lease liabilities were $297,619 and $338,542, respectively. The long-term portion of the operating lease liabilities, $237,892, is included in long-term obligations. As of June 30, 2023, the weighted-average discount rate for this operating lease was 5%. The future operating lease payments are guaranteed by a senior employee of the Company.

Stockholders' Equity Disclosure

Stockholders' Equity Disclosure	6 Months Ended
	Jun. 30, 2023
Notes
Stockholders' Equity Disclosure	(9) Stockholders’ Equity Effective January 13, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation (the “ Certificate of Amendment blank check In May 2023, the Company executed a subscription agreement with an accredited investor for the private sale of 400,000 shares of restricted common stock to the investor at a price of $0.10 per share. The $40,000 proceeds of this sale were used for working capital purposes. Pursuant to the subscription agreement, the Company also granted the investor an equal number of warrants to purchase additional shares of common stock at a price of $1.00 per share, which is only exercisable if the volume weighted average price of common stock exceeds $1.00 per share for a three day period. During the six months ended June 30, 2023, two holders of our convertible notes elected to convert some of their debt into shares of our common stock at the applicable conversion rates at the time of each conversion. In the first instance, the holder of a note on which we had defaulted in December 2022, elected to convert the remaining principal balance of $70,104, plus an additional default penalty of $42,552, into 317,803 shares of our common stock. In the second instance, the holder of a note with a principal balance of $74,250, elected to convert $12,000 of the note into 349,854 shares of our common stock at the calculated conversion price of approximately $0.035 per share (see Note 7). Effective April 1, 2022, the Company granted a common stock purchase warrant to a Washington, DC based firm that it has engaged to provide consulting services relating to certain federal regulatory matters. The warrant will enable the firm to purchase up to 360,000 shares of the Company’s common stock at an exercise price of $10.00 per share, or the lower of any public offering related conversion price, for a period of 10 years. The warrant is structured to be exercisable in six separate tranches of from 160,000 shares to 40,000 shares, assuming specified performance milestones are met by the firm for each tranche. Using the Black Scholes model, the Company has calculated the grant date value of this warrant to be $2,368,440. The Company will amortize this amount as stock compensation expense when the Company determines it is probable that each performance milestone will be met. As no such performance milestones have been met, the Company has not recognized any stock compensation expense applicable to such warrant of June 30, 2023. On February 11, 2022, the Company issued a total of 4,000 shares of common stock to the two principals of a private company as compensation for arranging a contingent purchase of lab equipment from them. The Company valued such shares at $5.00 per share resulting in recognizing non-cash compensation expense in the nine months ended September 30, 2022 in the amount of $20,000. Under the agreement with the principals of the private company, the Company may complete the purchase of the lab equipment at a later date by making a cash payment to them of $52,000 or, alternatively, the Company may elect to return the equipment to them. In either case, however, the two principals will retain the 4,000 shares of common stock as compensation. Effective March 31, 2021 and August 31, 2020, the Company reached the necessary milestones to trigger the conversion of certain notes payable issued on various dates in 2018 and 2019, as amended, into shares of the Company’s common stock, at conversion prices of $1.25 to $3.25 per share, subject to a 4.99% ownership limitation for each beneficial owner of such notes. In conjunction with these conversions, the holders of notes with total principal and accrued interest balances in the aggregate amount of $794,358 converted their notes into 433,203 shares of common stock, effective March 31, 2021, and the holders of notes with total principal and accrued interest balances in the aggregate amount of $501,137 converted their notes into 400,910 shares of common stock, effective August 31, 2020. As of June 30, 2023, convertible notes payable in the amount of $174,685, plus accrued interest in the amount of $53,568, remain outstanding and are available to be subsequently converted into 182,602 shares of common stock, subject to the ownership limitation (see Note 7). On December 29, 2020, the Board of Directors adopted, subject to the ratification by the majority shareholders, which ratification occurred pursuant to a majority shareholder consent, effective on December 30, 2020, the Rapid Therapeutic Science Laboratories, Inc. 2020 Equity Incentive Plan. Effective on January 7, 2022, the Board of Directors adopted, subject to the ratification by the majority shareholders, on January 11, 2022, the First Amended and Restated Rapid Therapeutic Science Laboratories, Inc. 2020 Equity Incentive Plan (the “ 2020 Plan The 2020 Plan provides an opportunity for any employee, officer, director or consultant of the Company, subject to limitations provided by federal or state securities laws, to receive (i) incentive stock options (to eligible employees only); (ii) nonqualified stock options; (iii) restricted stock; (iv) stock awards; (v) shares in performance of services; (vi) other stock-based awards; or (vii) any combination of the foregoing. In making such determinations, the Board of Directors may take into account the nature of the services rendered by such person, his or her present and potential contribution to the Company’s success, and such other factors as the Board of Directors in its discretion shall deem relevant. Subject to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common stock, or a reorganization or reclassification of the Company’s common stock, the aggregate number of shares of common stock which may be issued pursuant to awards under the 2020 Plan is the sum of (i) 1,000,000 shares, and (ii) an annual increase on March 1st of each calendar year, beginning in 2022 and ending in 2030, in each case subject to the approval of the Board of Directors or the compensation committee of the Company (if any) on or prior to the applicable date, equal to the lesser of (A) five percent (5%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year; (B) 1,000,000 shares of common stock; and (C) such smaller number of shares as determined by the Board of Directors or compensation committee of the of the Company (if any)(the “ Share Limit The maximum number of shares subject to awards granted during a single calendar year to any non-employee director, taken together with any cash fees paid during the compensation year to the non-employee director, in respect of the director’s service as a member of the Board during such year (including service as a member or chair of any committees of the Board), will not exceed $500,000 in total value (calculating the value of any such awards based on the grant date fair value of such awards for financial reporting purposes). Compensation will count towards this limit for the calendar year in which it was granted or earned, and not later when distributed, in the event it is deferred. Employees, non-employee directors, and consultants of the Company and its subsidiaries are eligible to participate in the 2020 Plan. Incentive stock options may be granted under the 2020 Plan only to employees of the Company and its affiliates. Employees, directors and consultants of the Company and its affiliates are eligible to receive all other types of awards under the 2020 Plan. No awards are issuable by the Company under the 2020 Plan (a) in connection with services associated with the offer or sale of securities in a capital-raising transaction; or (b) where the services directly or indirectly promote or maintain a market for the Company’s securities. The 2020 Plan will automatically terminate on the 10th anniversary of original approval date of the Plan (December 29, 2030). However, prior to that date, the Company’s Board of Directors may amend or terminate the 2020 Plan as it deems advisable, but it cannot adopt an amendment if it would (1) without a grantee’s consent, materially and adversely affect that grantee’s award; or (2) without shareholder approval, increase the number of shares of the Company’s common stock that can be awarded under the 2020 Plan, except as provided for therein. The Company has made no awards under the 2020 Plan to date. In March 2018, the Board approved the establishment of a 2018 Stock Option Plan with an authorization for the issuance of up to 800,000 shares of common stock. The Plan is designed to provide for future discretionary grants of stock options, stock awards and stock unit awards to key employees and non-employee directors. The Company has made no awards under the 2018 Stock Option Plan to date.

Related Party Transactions Disc

Related Party Transactions Disclosure	6 Months Ended
	Jun. 30, 2023
Notes
Related Party Transactions Disclosure	(10) Related Party Transactions Office services were provided without charge by our Chief Executive Officer and director, Donal R. Schmidt, Jr., from November 2019 to June 2021, at which time, the Company relocated to a new leased office location through December 2021. Pending completion of the build out of the new office and lab space in Addison, Texas (see Note 6), the Company relocated back to the office space in Dallas, Texas, provided by Mr. Schmidt, under an arrangement whereby the Company was responsible for a relatively small share of office costs during its occupancy from January 2022 to April 2023, but with no long-term financial commitment. In May 2023, the Company relocated to the residence of Mr. Schmidt in De Leon, Texas, at no incremental cost to the Company. As indicated in Note 7, the Company has received unsecured cash advances from Mr. Schmidt and another officer, Sean Berrier, to cover corporate expenses beginning in May 2021. In addition, since the fourth quarter of 2022, Mr. Schmidt, has made other “in lieu” advances by paying certain corporate expenses on behalf of the Company via unreimbursed charges on his personal credit card. As of June 30, 2023, the net amount of all such advances was $416,860. This amount includes corporate expenses that were paid by Mr. Schmidt on behalf of the Company in the six months ended June 30, 2023 in the amount of $58,659. These related party advances accrue interest at the rate of 1% per annum and are payable on demand. Also as indicated in Note 7, the Company issued a promissory note to an independent director, Scott Suggs, for an unsecured, interest-bearing loan received from him in January 2022 in the amount of $400,000. Such note was issued to Mr. Suggs with a one year maturity, however, he has agreed to extend the maturity to a date to be determined. The officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company’s Board of Directors is tasked with resolving related party conflicts.

Employer Tax Refund

Employer Tax Refund	6 Months Ended
	Jun. 30, 2023
Notes
Employer Tax Refund	(11) Employer Tax Refund Pursuant to tax relief granted to employers by the federal government following the impact of the Covid 19 pandemic beginning in March 2020 (see Note 1), the Company became eligible for a refund of a portion of its payroll taxes that were paid in the years ended December 31, 2020 and 2021. In January 2023, the Company applied for a refund of a portion of its 2020 and 2021 payroll taxes by amending its quarterly payroll tax returns filed in those years, using the services of a financial intermediary in the process. As of June 30, 2023, the Company determined that its amended payroll tax returns for those periods had been approved by the taxing authority and that the Company would receive a refund of such taxes paid in the total amount of $110,038. In anticipation of this refund, the Company recognized a non-operating gain in other income and an offsetting receivable in current assets in the net amount of $82,529 as of June 30, 2023, which reflected a fee of $27,509 owing to the intermediary. In July 2023, the Company received the full amount of the anticipated refund from the taxing authority and paid the fee to the intermediary.

Commitments and Contingencies,

Commitments and Contingencies, Disclosure	6 Months Ended
	Jun. 30, 2023
Notes
Commitments and Contingencies, Disclosure	(12) Commitments and Contingencies From time to time in the ordinary course of our business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We currently have no insurance policies covering such potential losses.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Notes
Subsequent Events	(13) Subsequent Events Management has evaluated events subsequent to the six months ended June 30, 2023 up to August 14, 2023, for transactions and other events that may require adjustment of and/or disclosure in the consolidated financial statements, noting none.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies: Basis of Accounting Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Basis of Accounting Policy	Basis of Accounting

Summary of Significant Accoun_3

Summary of Significant Accounting Policies: Reverse Stock Split Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Reverse Stock Split Policy	Reverse Stock Split

Summary of Significant Accoun_4

Summary of Significant Accounting Policies: Principles of Consolidation, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Principles of Consolidation, Policy	Principles of Consolidation

Summary of Significant Accoun_5

Summary of Significant Accounting Policies: Cash and Cash Equivalents Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Cash and Cash Equivalents Policy	Cash and Cash Equivalents

Summary of Significant Accoun_6

Summary of Significant Accounting Policies: Inventory, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Inventory, Policy	Inventory

Summary of Significant Accoun_7

Summary of Significant Accounting Policies: Property and Equipment, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Property and Equipment, Policy	Property and Equipment

Summary of Significant Accoun_8

Summary of Significant Accounting Policies: Intangible Assets, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Intangible Assets, Policy	Intangible Assets

Summary of Significant Accoun_9

Summary of Significant Accounting Policies: Revenue Recognition, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Revenue Recognition, Policy	Revenue recognition FASB ASU Revenue from Contracts with Customers (Topic 606)

Summary of Significant Accou_10

Summary of Significant Accounting Policies: Earnings per share, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Earnings per share, Policy	Earnings per Share

Summary of Significant Accou_11

Summary of Significant Accounting Policies: Income Taxes, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Income Taxes, Policy	Income Taxes

Summary of Significant Accou_12

Summary of Significant Accounting Policies: Use of Estimates, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Use of Estimates, Policy	Use of Estimates Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from estimates.

Summary of Significant Accou_13

Summary of Significant Accounting Policies: Fair value of financial instruments, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Fair value of financial instruments, Policy	Fair Value of Financial Instruments Level 1: The preferred inputs to valuation efforts are “ quoted prices in active markets for identical assets or liabilities Level 2: FASB acknowledged that active markets for identical assets and liabilities are relatively uncommon and, even when they do exist, they may be too thin to provide reliable information. To deal with this shortage of direct data, the board provided a second level of inputs that can be applied in three situations. Level 3: If inputs from levels 1 and 2 are not available, FASB acknowledges that fair value measures of many assets and liabilities are less precise. The board describes Level 3 inputs as “ unobservable shall be used to measure fair value to the extent that observable inputs are not available for situations in which there is little, if any, market activity for the asset or liability at the measurement date observable inputs The Company’s financial instruments consist of cash, tax refund receivable, accounts payable and accrued liabilities, notes payable, due to related parties, warrant liabilities and derivative liabilities. Except for cash, warrant liabilities, and derivative liabilities, the Company’s financial instruments’ carrying amounts, excluding unamortized discounts, approximate their fair values due to their short term to maturity. Cash is measured and recognized at fair value based on level 1 inputs for all periods presented. Warrant liabilities and Derivative liabilities are measured and recognized at fair value based on level 3 inputs.

Summary of Significant Accou_14

Summary of Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements

Summary of Significant Accou_15

Summary of Significant Accounting Policies: Subsequent Events, Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Policies
Subsequent Events, Policy	Subsequent Events

Property and Equipment Disclo_2

Property and Equipment Disclosure: Schedule of Property and Equipment Balances (Tables)	6 Months Ended
	Jun. 30, 2023
Tables/Schedules
Schedule of Property and Equipment Balances	June 30, 2023 December 31, 2022 Equipment purchased from Razor Jacket, LLC and awaiting installation in the Company’s facilities in Addison, Texas $ 500,000 $ 500,000 Equipment located in the Company’s facilities in Dallas, Texas 221,412 221,412 Leasehold improvements in progress at the Company’s new facilities in Addison, Texas 630,160 840,591 Leasehold improvements in the Company’s existing facilities in Dallas, Texas 2,500 2,500 Total property and equipment 1,354,072 1,564,503 Less: Accumulated depreciation (65,313) (53,327) Net property and equipment $ 1,288,759 $ 1,511,176

Notes Payable Disclosure_ Sched

Notes Payable Disclosure: Schedule of long-term debt obligations (Tables)	6 Months Ended
	Jun. 30, 2023
Tables/Schedules
Schedule of long-term debt obligations	June 30, 2023 December 31 2022 Non-Related Parties Convertible debenture issued to an accredited investor on August 4, 2021, in principal amount of $1,941,176, original issue discount of 15%, convertible at option of investor into a total of 194,118 shares of common stock at $10.00 per share, payable upon earlier of a qualified offering, uplisting on national exchange, convertible at 25% discount to the price per share of common stock in a qualified offering, past due nominal maturity. $ 1,941,176 $ 1,941,176 Convertible debenture issued to an accredited investor on May 31, 2022, in principal amount of $411,764, original issue discount of 15%, convertible at option of investor into a total of 41,176 shares of common stock at $10.00 per share, payable upon earlier of a qualified offering, uplisting on national exchange, convertible at 25% discount to the price per share of common stock in a qualified offering, past due nominal maturity. 411,764 411,764 Convertible promissory notes issued to an accredited investor on November 15, 2019, maturing in 5 years, accruing interest at 5% per annum, convertible into common stock at $1.25 per share. 150,000 150,000 Other short term notes issued to various affiliates of the former owners of Power Blockchain for acquisition of Treasury Stock, computers and equipment, and working capital financing, at stated interest rates of 10%. Amended on November 15, 2019, to be convertible into common stock at $1.25 per share. Of this amount, $23,700 pertains to a related party. 48,386 48,386 Promissory note issued to an institutional investor on March 8, 2022, accruing interest at approximately 8% per annum, due in one year, in default and fully converted as of June 30, 2023. - 70,104 Convertible note issued to an accredited investor on July 25, 2022, net of unamortized debt discount of $4,933 and partial conversion of $12,000 (see further discussion below). 57,317 33,603 Convertible note issued to an accredited investor on February 3, 2023, net of unamortized debt discount of $32,401 (see further discussion below). 21,849 - Related Parties Unsecured advances received from two officers beginning in May 2021 and continuing through March 2023, accruing interest at 1% per annum, payable on demand. 416,860 396,902 Promissory note issued to an independent director on January 28, 2022, accruing interest at approximately 18% per annum, currently past due nominal maturity. 400,000 400,000 Total notes payable 3,447,352 3,451,935 Current portion of notes payable (3,297,352) (3,301,935) Long term portion of notes payable $ 150,000 $ 150,000

Notes Payable Disclosure_ Futur

Notes Payable Disclosure: Future maturities of notes payable (Tables)	6 Months Ended
	Jun. 30, 2023
Tables/Schedules
Future maturities of notes payable	Year ending June 30, 2024 $ 3,334,686 Year ending June 30, 2025 150,000 $ 3,484,686

Long Term Lease Obligation Di_2

Long Term Lease Obligation Disclosure: Future operating lease minimum payments (Tables)	6 Months Ended
	Jun. 30, 2023
Tables/Schedules
Future operating lease minimum payments	Year ending December 31, 2023 $ 44,972 Year ending December 31, 2024 102,792 Year ending December 31, 2025 107,075 Year ending December 31, 2026 111,358 Total future minimum lease payments 366,197 Less amounts representing interest (27,655) Present value of lease liability 338,542 Current portion of operating lease liability (100,650) Long-term portion of operating lease liability $ 237,892

Summary of Significant Accou_16

Summary of Significant Accounting Policies: Reverse Stock Split Policy (Details) - shares shares in Millions	Jun. 30, 2022	Mar. 30, 2022	Jan. 13, 2020
Details
Common stock authorized, increase	800	800	750

Going Concern Disclosure (Detai

Going Concern Disclosure (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Details
Accumulated deficit	$ 10,078,456	$ 10,316,149
Working capital deficit	$ 4,107,695

License Agreement Disclosure (D

License Agreement Disclosure (Details) - USD ($)	6 Months Ended		24 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021
Additions to property and equipment	$ 0	$ 354,800
Sublicense agreement, net	170,075			$ 170,075
Sublicense agreement with Texas MDI
Stock issued in acquisition of assets, shares			5,600,000
Stock issued in acquisition of assets, value			$ 140,000
Total purchase amount of intangible asset			200,000
Additions to property and equipment			135,000
Accrued liabilities, net			$ 44,925
Sublicense agreement, gross					$ 200,000
Sublicense agreement, net	$ 170,075

Prior Asset Acquisition Discl_2

Prior Asset Acquisition Disclosure (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2021
General and administrative expense	$ 97,739	$ 122,382	$ 190,040	$ 905,782
Asset Purchase and Sales Agreement with Razor Jacket, Cash Paid
Cash paid for acquisition					$ 300,000
Shares issued for acquisition					25,000
Shares issuable for acquisition					16,500,000
General and administrative expense					$ 300,000
Asset Purchase and Sales Agreement with Razor Jacket, Stock Issued
Stock issued in acquisition of assets, shares					25,000
Contingent consideration approved in acquisition of assets, shares					16,500,000

Property and Equipment Disclo_3

Property and Equipment Disclosure: Schedule of Property and Equipment Balances (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Property and equipment, gross	$ 1,354,072	$ 1,564,503
Accumulated depreciation	(65,313)	(53,327)
Net property and equipment	1,288,759	1,511,176
Equipment purchased from Razor Jacket
Property and equipment, gross	500,000	500,000
Equipment located in the Company's facilities
Property and equipment, gross	221,412	221,412
Leasehold improvements in progress at new facilities
Property and equipment, gross	630,160	840,591
Leasehold improvements in the Company's facilities
Property and equipment, gross	$ 2,500	$ 2,500

Property and Equipment Disclo_4

Property and Equipment Disclosure (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Accounts payableand accrued liabilities, net	$ 769,957	$ 891,408
Commercial lease at new facilities
Capitalized leasehold improvements	630,160
Accounts payableand accrued liabilities, net	$ 100,000

Notes Payable Disclosure_ Sch_2

Notes Payable Disclosure: Schedule of long-term debt obligations (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Convertible debt payable	$ 3,447,352	$ 3,451,935
Current portion of notes payable	3,297,352	3,301,935
Convertible notes payable	150,000	150,000
Convertible debenture issued to an accredited investor, Aug 4 2021
Convertible debt payable	1,941,176	1,941,176
Convertible debenture issued to an accredited investor on May 31, 2022
Convertible debt payable	411,764	411,764
Convertible promissory notes issued to two accredited investors, Nov 15 2019
Convertible debt payable	150,000	150,000
Other short term notes issued to various affiliates
Convertible debt payable	48,386	48,386
Promissory note issued to an institutional investor
Convertible debt payable	0	70,104
Convertible note issued to accredited investor, July 25, 2022
Convertible debt payable	57,317	33,603
Convertible note issued to an accredited investor on February 3, 2023
Convertible debt payable	21,849	0
Unsecured advances received from two officers
Convertible debt payable	416,860	396,902
Promissory note issued to an independent director
Convertible debt payable	$ 400,000	$ 400,000

Notes Payable Disclosure (Detai

Notes Payable Disclosure (Details) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	May 30, 2022	Aug. 04, 2021
Warrant liability	$ 30,195			$ 30,195		$ 508,593
Derivative liability	53,568			53,568		40,647
Gain (loss) on valuation of warrant liability	128,456		$ 857,127	529,047	$ 780,082
Convertible debt payable	3,447,352			3,447,352		3,451,935
Proceeds from notes payable - related party				0	423,000
Stock issued for conversion of debt, value	12,000	$ 112,656
Accrued interest payable	$ 173,856			$ 173,856		$ 124,736
Convertible debenture issued to an accredited investor, Aug 4 2021
Debt amount, gross											$ 1,941,176
Proceeds from Issuance of convertible debenture payable							$ 1,650,000
Warrants issued						194,118	194,118
Exercise price per share	$ 10			$ 10							$ 10
Discount to offering price											25%
Convertible debt payable	$ 1,941,176			$ 1,941,176		$ 1,941,176
Convertible debenture issued to an accredited investor on May 31, 2022
Debt amount, gross										$ 1,941,176
Proceeds from Issuance of convertible debenture payable						$ 411,764
Warrants issued						388,236
Exercise price per share	$ 10			$ 10
Convertible debt payable	$ 411,764			$ 411,764		$ 411,764
Convertible debenture Placement Agent
Warrants issued						9,706
Exercise price per share						$ 10
Warrant liability							$ 1,717,213
Convertible debenture Warrants issued
Derivative liability	10,395			10,395
Gain (loss) on valuation of warrant liability				130,220
Convertible debt Warrants issued, additional tranche
Warrants issued						388,236
Warrant liability	19,800			19,800
Gain (loss) on valuation of warrant liability				348,178
Unsecured advances received from two officers
Convertible debt payable	416,860			416,860		$ 396,902
Convertible note issued to an accredited investor on February 3, 2023
Proceeds from Issuance of convertible debenture payable				54,250
Convertible debt payable	21,849			21,849		0
Convertible note issued to accredited investor, July 25, 2022
Proceeds from Issuance of convertible debenture payable						74,250
Convertible debt payable	57,317			57,317		33,603
Two short-term loans, Jan and March 2022
Debt amount, gross						597,000
Loan was from an independent director
Proceeds from notes payable - related party					$ 400,000
Jan and March loan, conversion1
Stock issued for conversion of debt, value				$ 12,000		$ 15,000
Stock issued for conversion of debt, shares				349,854		16,340
Promissory note issued to an institutional investor
Convertible debt payable	0			$ 0		$ 70,104
Jan and March loan, conversion2
Stock issued for conversion of debt, value				$ 70,104
Stock issued for conversion of debt, shares				317,803
Various notes in 2018 and 2019
Stock issued for conversion of debt, value							$ 794,358	$ 501,137
Stock issued for conversion of debt, shares							433,203	400,910
Conversion price per share							$ 3.25
Convertible notes payable, gross	174,685			$ 174,685
Accrued interest payable	$ 53,568			$ 53,568
Promissory notes with two accredited investors
Proceeds from notes payable - related party									$ 300,000
Stock issued for conversion of debt, value									$ 2,034,760
Stock issued for conversion of debt, shares									626,080
Convertible promissory notes, from June to Aug 2020
Conversion price per share									$ 1.25

Long Term Lease Obligation Di_3

Long Term Lease Obligation Disclosure: Future operating lease minimum payments (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Details
Due December 31, 2023	$ 44,972
Due December 31, 2024	102,792
Due December 31, 2025	107,075
Due December 31, 2026	111,358
Current portion of operating lease obligation	100,650	$ 98,509
Long-term portion of operating lease obligation	$ 237,892	$ 280,235

Long Term Lease Obligation Di_4

Long Term Lease Obligation Disclosure (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Details
Operating lease right-of-use asset, net	$ 297,619	$ 340,136
Operating lease obligation	338,542
Long-term portion of operating lease obligation	$ 237,892	$ 280,235
Operating lease discount rate	5%

Stockholders' Equity Disclosu_2

Stockholders' Equity Disclosure (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Mar. 24, 2023	Mar. 31, 2022	Mar. 30, 2022	Jan. 13, 2020
Common stock authorized, increase				800,000,000						800,000,000	750,000,000
Preferred stock share, increase									100,000,000
Stock issued for cash, shares	400,000
Stock issued for cash, price per share	$ 0.10		$ 0.10
Stock issued for cash, value	$ 40,000
Stock issued for conversion of debt, value	12,000	$ 112,656
Stock-based compensation expense			$ 0	$ 79,210
Accrued interest payable	$ 173,856		$ 173,856		$ 124,736
Common stock purchase agreement, consulting services
Warrants issued, other					360,000
Exercise price per share	$ 10		$ 10
Derivative liabilities	$ 2,368,440		$ 2,368,440
Compensation for a contingent purchase of lab equipment
Share-based compensation, shares issued				4,000
Stock-based compensation expense				$ 20,000
2020 Equity Incentive Plan
Common stock authorized under Stock Option Plan	10,000,000		10,000,000					388,152
2018 Stock Option Plan
Common stock authorized under Stock Option Plan	800,000		800,000
Jan and March loan, conversion2
Stock issued for conversion of debt, value			$ 70,104
Stock issued for conversion of debt, shares			317,803
Jan and March loan, conversion1
Stock issued for conversion of debt, value			$ 12,000		$ 15,000
Stock issued for conversion of debt, shares			349,854		16,340
Various notes in 2018 and 2019
Stock issued for conversion of debt, value						$ 794,358	$ 501,137
Stock issued for conversion of debt, shares						433,203	400,910
Conversion price per share						$ 3.25
Convertible notes payable, gross	$ 174,685		$ 174,685
Accrued interest payable	$ 53,568		$ 53,568
Series A Preferred Stock
Preferred Stock, Shares Authorized	16,500,000		16,500,000
Series B Preferred Stock
Preferred Stock, Shares Authorized	2,000,000		2,000,000
Series C Preferred Stock
Preferred Stock, Shares Authorized	8,500,000		8,500,000

Related Party Transactions Di_2

Related Party Transactions Disclosure (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Convertible debt payable	$ 3,447,352	$ 3,451,935
Unsecured advances received from two officers
Convertible debt payable	416,860	396,902
Expenses paid by related party	58,659
Promissory note issued to an independent director
Convertible debt payable	$ 400,000	$ 400,000

Employer Tax Refund (Details)

Employer Tax Refund (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Details
Employer tax refund receivable, gross	$ 110,038
Employer tax refund receivable	82,529	$ 0
Employer tax refund receivable, fee to the intermidiary	$ 27,509